Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425450 | 0.77 | CHRM3 (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4425083 | 0.73 | CHRM3 (0.37) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1286191 | 0.69 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24244147 | 0.64 | — | — | |
| SCHEMBL18557111 | 0.64 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3140913 | 0.64 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18557124 | 0.64 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18557126 | 0.64 | CHRM3 (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24554449 | 0.64 | NOS3 (0.31) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL855820 | 0.61 | PIK3CA (0.38) | CHRM3PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2006-04-06 | — | — | US | claimed |
| EP-1499598-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2005-01-26 | — | — | EP | claimed |
| WO-2003087064-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2003-10-23 | — | — | WO | claimed |
| US-7544675-B2 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2009-06-09 | — | — | US | disclosed |
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | PDE7A, CHRM3, PDE4B | CHRM3 2/4885PDE4A 5/4885PDE4B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.